Name: | maraviroc |
---|---|
PubChem Compound ID: | 3002977 |
Molecular formula: | C29H41F2N5O |
Molecular weight: | 513.666 g/mol |
Synonyms: |
376348-65-1; AIDS104834; Maraviroc; UK 427857; UK-427,857; exo-4,4-Difluoro-N-[3-[3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]oct-8-yl]-1(S)-phenylpropyl]cyclohexanecarboxamide; UK-427857; 674782-29-7; AIDS-104834; Cyclohexanecarboxamide, 4,4-difluoro-N-((1S)-3-((3-exo)-3-(3-methyl-5-(1-methylethyl)-4H-1,2,4-triazol-4-yl)-8-azabicyclo(3.2.1)oct-8-yl)-1-phenylpropyl)-
|
Name: | maraviroc |
---|---|
Name (isomeric): | DB04835 |
Drug Type: | small molecule |
Brand: | Selzentry, Celsentri |
Category: | Anti-HIV Agents |
CAS number: | 376348-65-1 |
Indication: | For treatment-experienced adult patients infected with only CCR5-tropic HIV-1 detectable, who have evidence of viral replication and HIV-1 strains resistant to multiple antiretroviral agents. |
---|---|
Pharmacology: | Maraviroc is a chemokine receptor antagonist drug developed by the drug company Pfizer that is designed to act against HIV by interfering with the interaction between HIV and CCR5. |
Mechanism of Action: |
Maraviroc is an entry inhibitor and works by blocking HIV from entering human cells. Specifically maraviroc is a selective, slowly reversible, small molecule antagonist of the interaction between human CCR5 and HIV-1 gp120. Maraviroc selectively binds to the human chemokine receptor CCR5 present on the membrane of CD4 cells (T-cells), preventing th...
show more » |
Absorption: | The absolute oral bioavailability of a 100 mg dose is 23% and is predicted to be 33% at 300 mg. Coadministration of a 300mg tablet with a high fat breakfast reduced maraviroc Cmax and AUC by 33% in healthy volunteers. |
Protein binding: | Approximately 76% bound to human plasma proteins, with moderate affinity for albumin and alpha-1 acid glycoprotein. |
Biotransformation: | In vitro studies indicate that CYP3A is the major enzyme responsible for maraviroc metabolism. |
Half Life: | 14-18 hours |
Affected organisms: | Human Immunodeficiency Virus |
Drug interaction: |
|
---|